Dr Ramsdale who will remain as a non-executive director, will assume the chair of Alchemia’s Scientific Advisory Board and will become a consultant to the company.
Dr Smith has founded and led biotech companies in the United Kingdom and Australia and brings with him almost 10 years experience as a top-rated pharmaceutical industry analyst with UBS and HSBC, both leading international investment banks.
Dr Smith was Chief Executive Officer and Managing Director of Amrad Corporation Limited (2003-05) where he implemented a new business strategy focusing Amrad (later Zenyth Therapeutics) on antibody-based therapies. Zenyth was acquired by CSL in 2006 and as part of the reorganisation Amrad created the spin-out anti-infective company Avexa (ASX:AVX).
Retiring CEO Dr Ramsdale congratulated Dr Smith on his appointment and lauded his reputation as one of the most experienced and widely respected executives in the Australian biotech industry.
“I have worked closely with Peter for the past year and I am convinced he is the right person to lead Alchemia through its next phase of critical growth,” Dr Ramsdale said.
“Peter brings more than 18 years of relevant commercial experience in the biotechnology-pharmaceutical industry. “His international network of relationships has been instrumental in securing the new manufacturing and marketing partnerships for synthetic heparin announced today, adding significant value to Alchemia going forward,” said Dr Ramsdale.
Alchemia Limited
ABN 43 071 666 334
3 Hi-Tech Court, Brisbane Technology Park, Eight Mile Plains QLD 4113
PO Box 6242, Upper Mt Gravatt Qld 4122
Phone 61-7-3340 0200 Fax 61-7-3340 0222 E-mail: enquiries@alchemia.com.au
World Wide Web: www.alchemia.com
